{"entity":{"id":"nct06018337","kind":"trial","name":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Bre","aka":["DYNASTY-Breast02"],"tldr":"A phase 3 trial of Trastuzumab pamirtecan run by DualityBio Inc., active.","summary":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) is a phase 3 interventional study registered as NCT06018337 by DualityBio Inc., with 541 participants enrolled, started 2024-01-18. Conditions listed: Metastatic Breast Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06018337","url":"https://clinicaltrials.gov/study/NCT06018337"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","her2-low-metastatic-breast-cancer"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["trastuzumab-pamirtecan"],"companies":["dualitybio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06018337","phase":"3","setting":"A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)","sponsor":"DualityBio Inc.","started":"2024-01-18","startedType":"actual","enrolled":541,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06018337/","neighbours":{"cancer":[{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"trastuzumab-pamirtecan","kind":"drug","name":"Trastuzumab pamirtecan","route":"/drugs/trastuzumab-pamirtecan/"}],"company":[{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/"}]}}